Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 20/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3603737 | 1.00 | GPR88 (0.43) | GPR88 | |
| Trifluoroacetic Acid SCHEMBL3610727 | 0.77 | KDM1A (0.48) | — | |
| Trifluoroacetic Acid SCHEMBL3610726 | 0.77 | KDM1A (0.48) | — | |
| SCHEMBL3606263 | 0.75 | TP53 (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL3606486 | 0.75 | APP (0.41) | GPR88 | |
| Trifluoroacetic Acid SCHEMBL3601567 | 0.75 | KDM1A (0.41) | — | |
| Trifluoroacetic Acid SCHEMBL3606489 | 0.75 | APP (0.41) | GPR88 | |
| Trifluoroacetic Acid SCHEMBL3601568 | 0.75 | KDM1A (0.41) | — | |
| Trifluoroacetic Acid SCHEMBL3608309 | 0.73 | SIGMAR1 (0.51) | — | |
| Trifluoroacetic Acid SCHEMBL3608311 | 0.73 | SIGMAR1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121612-B1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| US-8299102-B2 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2121612-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008080511-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | WO | disclosed |
| EP-1942104-A1 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | PTGIS, TBXAS1, EDNRA | GPR88 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.